Meeting
2017 Genitourinary Cancers Symposium
An oral androgen receptor PROTAC degrader for prostate cancer.
Authors
Taavi K Neklesa
Arvinas, New Haven, CT
Taavi K Neklesa , Lawrence B Snyder , Mark Bookbinder , Xin Chen , Andrew P Crew , Craig M Crews , Hanqing Dong , Deborah A Gordon , Kanak Raina , AnnMarie K Rossi , Ian Taylor , Nicholas Vitale , Jing Wang , Ryan R Willard , Kurt Zimmermann
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Prostate Cancer,Urothelial Carcinoma,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 273)
DOI
10.1200/JCO.2017.35.6_suppl.273
Abstract #
273
Poster Bd #
D13
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
ARV-110: An oral androgen receptor PROTAC degrader for prostate cancer.
First Author: Taavi Neklesa
Poster
2018 Genitourinary Cancers Symposium
An oral androgen receptor PROTAC degrader for prostate cancer.
First Author: Taavi Neklesa
Poster
2019 Genitourinary Cancers Symposium
Measurement science of the androgen receptor splice variant-7 protein in primary and castration-resistant prostate cancer tissue.
First Author: Adam Sharp
Poster
2018 Genitourinary Cancers Symposium
A phase Ib/II trial of indomethacin and enzalutamide to treat castration-resistant prostate cancer (CRPC).
First Author: Chong-xian Pan